Cyclin-Dependent Kinase 4/6 Inhibitors for the Treatment of Breast Cancer: A Review of Preclinical and Clinical Data

Clinical Breast Cancer

Volumn 16, Issue 1, 2016, Pages 8-17

  Vidula, Neelima ^a   Rugo, Hope S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Abemaciclib; CDK 4 6 inhibitors; Hormone receptor positive breast cancer; Palbociclib; Ribociclib

Indexed keywords

ABEMACICLIB; ANTINEOPLASTIC AGENT; PALBOCICLIB; RADIOSENSITIZING AGENT; RIBOCICLIB; TAMOXIFEN; 5-(4-ETHYLPIPERAZIN-1-YLMETHYL)PYRIDIN-2-YL)-(5-FLUORO-4-(7-FLUORO-3-ISOPROPYL-2-METHYL-3H-BENZIMIDAZOL-5-YL)PYRIMIDIN-2-YL)AMINE; AMINOPYRIDINE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PURINE DERIVATIVE; PYRIDINE DERIVATIVE;

ANEMIA; BREAST CANCER; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CELL CYCLE; CYTOPENIA; DIARRHEA; DRUG MECHANISM; DRUG POTENTIATION; FATIGUE; FEBRILE NEUTROPENIA; HORMONAL THERAPY; HUMAN; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; VOMITING; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; FEMALE;

AMINOPYRIDINES; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BREAST NEOPLASMS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; FEMALE; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PURINES; PYRIDINES;

EID: 84951865637     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2015.07.005     Document Type: Review

References (75)

1. US Food and Drug Administration. US Department of Health and Human Services. Palbociclib. Available at: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm432886.htm. Accessed February 12, 2015.
2. N.C. Turner, J. Ro, F. Andre, and et al. Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 373 2015 209 219
3. th ed. 2002 Garland Science New York, NY
4. D. Zardavas, J. Baselga, and M. Piccart Emerging targeted agents in metastatic breast cancer Nat Rev Clin Oncol 10 2013 191 210
5. M.A. Dickson Molecular pathways: CDK4 inhibitors for cancer therapy Clin Cancer Res 20 2014 3379 3383
6. D.W. Fry, P.J. Harvey, P.R. Keller, and et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts Mol Cancer Ther 3 2004 1427 1438
7. D.W. Fry, D.C. Bedford, P.H. Harvey, and et al. Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6 J Biol Chem 276 2001 16617 16623
8. Y.J. Choi, and L. Anders Signaling through cyclin D-dependent kinases Oncogene 33 2014 1890 1903
9. J.L. Ferrer, J. Dupuy, F. Borel, L. Jacquamet, J.P. Noel, and V. Dulic Structural basis for the modulation of CDK-dependent/independent activity of cyclin D1 Cell Cycle 5 2006 2760 2768
10. J. Wesierska-Gadek, and M.P. Kramer The impact of multi-targeted cyclin-dependent kinase inhibition in breast cancer cells: clinical implications Expert Opin Investig Drugs 20 2011 1611 1628
11. N. Vasan, R. Yelensky, K. Wang, and et al. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice Oncologist 19 2014 453 458
12. M.C. Casimiro, M. Velasco-Velazquez, C. Aguirre-Alvarado, and R.G. Pestell Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present Expert Opin Investig Drugs 23 2014 295 304
13. B.W. Parker, G. Kaur, W. Nieves-Neira, and et al. Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol Blood 91 1998 458 465
14. J.C. Byrd, B.L. Peterson, J. Gabrilove, and et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805 Clin Cancer Res 11 2005 4176 4181
15. C. Li, L. Qi, A.C. Bellail, C. Hao, and T. Liu PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis Oncol Lett 7 2014 1673 1678
16. R.S. Finn, J. Dering, D. Conklin, and et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Res 11 2009 R77
17. Y. Sun, Y.X. Li, H.J. Wu, and et al. Effects of an indolocarbazole-derived CDK4 inhibitor on breast cancer cells J Cancer 2 2011 36 51
18. J.L. Dean, C. Thangavel, A.K. McClendon, C.A. Reed, and E.S. Knudsen Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure Oncogene 29 2010 4018 4032
19. Y.X. Zhang, E. Sicinska, J.T. Czaplinski, and et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo Mol Cancer Ther 13 2014 2184 2193
20. J. Rader, M.R. Russell, L.S. Hart, and et al. Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma Clin Cancer Res 19 2013 6173 6182
21. K.S. Joshi, M.J. Rathos, R.D. Joshi, and et al. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00 Mol Cancer Ther 6 2007 918 925
22. S. Zelivianski, A. Cooley, R. Kall, and J.S. Jeruss Cyclin-dependent kinase 4-mediated phosphorylation inhibits Smad3 activity in cyclin D-overexpressing breast cancer cells Mol Cancer Res 8 2010 1375 1387
23. O.W. Prall, B. Sarcevic, E.A. Musgrove, C.K. Watts, and R.L. Sutherland Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2 J Biol Chem 272 1997 10882 10894
24. C.K. Watts, A. Brady, B. Sarcevic, A. deFazio, E.A. Musgrove, and R.L. Sutherland Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation Mol Endocrinol 9 1995 1804 1813
25. A.J. Skildum, S. Mukherjee, and S.E. Conrad The cyclin-dependent kinase inhibitor p21WAF1/Cip1 is an antiestrogen-regulated inhibitor of Cdk4 in human breast cancer cells J Biol Chem 277 2002 5145 5152
26. X.H. Pei, F. Bai, M.D. Smith, and et al. CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis Cancer Cell 15 2009 389 401
27. C.E. Caldon, C.M. Sergio, J. Kang, and et al. Cyclin E2 overexpression is associated with endocrine resistance but not insensitivity to CDK2 inhibition in human breast cancer cells Mol Cancer Ther 11 2012 1488 1499
28. R. Zhao, H.Y. Yang, J. Shin, and et al. CDK inhibitor p57 (Kip2) is downregulated by Akt during HER2-mediated tumorigenicity Cell Cycle 12 2013 935 943
29. S.R. Vora, D. Juric, N. Kim, and et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K Inhibitors Cancer Cell 26 2014 136 149
30. C. Yu, M. Rahmani, Y. Dai, and et al. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process Cancer Res 63 2003 1822 1833
31. Y.H. Choi, and Y.H. Yoo Taxol-induced growth arrest and apoptosis is associated with the upregulation of the Cdk inhibitor, p21WAF1/CIP1, in human breast cancer cells Oncol Rep 28 2012 2163 2169
32. P.J. Roberts, J.E. Bisi, J.C. Strum, and et al. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy J Natl Cancer Inst 104 2012 476 487
33. J.L. Dean, A.K. McClendon, and E.S. Knudsen Modification of the DNA damage response by therapeutic CDK4/6 inhibition J Biol Chem 287 2012 29075 29087
34. N. Johnson, and G.I. Shapiro Cyclin-dependent kinase 4/6 inhibition in cancer therapy Cell Cycle 11 2012 3913
35. X. Huang, M. Di Liberto, D. Jayabalan, and et al. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4 Blood 120 2012 1095 1106
36. K.R. Hagen, X. Zeng, M.Y. Lee, and et al. Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis Cell Div 8 2013 10
37. A. DeMichele, A.S. Clark, D. Heitjan, and et al. A phase II trial of an oral CDK 4/6 inhibitor, PD0332991, in advanced breast cancer (abstract 519) J Clin Oncol suppl 2013 31
38. R.S. Finn, J.P. Crown, I. Lang, and et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol 16 2015 25 35
39. + BrCa. National Cancer Institute at the National Institutes of Health Clinical Trials. Available at: https://clinicaltrials.gov/ct2/show/NCT02040857 Accessed August 12, 2015.
40. NIH. National Cancer Institute. A study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer (PALOMA-2). Available at: https://clinicaltrials.gov/ct2/show/NCT01740427 Accessed August 12, 2015.
41. NIH. National Cancer Institute. Letrozole and CDK 4/6 inhibitor for ER positive, HER2 negative breast cancer in postmenopausal women. Available at: https://clinicaltrials.gov/ct2/show/NCT01709370 Accessed August 12, 2015.
42. PD 0332991 and anastrozole for stage 2 or 3 estrogen receptor positive and HER2 negative breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials Available at: https://clinicaltrials.gov/ct2/show/NCT01723774 Accessed August 12, 2015.
43. Palbociclib (PD-0332991) combined with fulvestrant in hormone receptor+ HER2-negative metastatic breast cancer after endocrine failure (PALOMA-3). National Cancer Institute at the National Institutes of Health Clinical Trials. Available at: https://clinicaltrials.gov/ct2/show/NCT01942135 Accessed August 12, 2015.
44. A study of palbociclib in addition to standard endocrine treatment in hormone receptor positive Her2 normal patients with residual disease after neoadjuvant chemotherapy and surgery (PENELOPE-B). Available at: http://clinicaltrials.gov/show/NCT01864746. Accessed May 16, 2014.
45. Clinicaltrials.gov [Web site]. Phase III study of palbociclib (PD-0332991) in combination with exemestane versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with resistance to non-steroidal aromatase inhibitors (PEARL). Available at: http://clinicaltrials.gov/ct2/show/NCT02028507. Accessed May 16, 2014.
46. NIH. National Cancer Institute. Study of LEE011, BYL719 and letrozole in advanced ER+ breast cancer. Available at: http://www.cancer.gov/clinicaltrials/search/view?cdrid=750319&version=HealthProfessional&protocolsearchid=12773476. Accessed May 27, 2014.
47. Clinicaltrials.gov [Web site]. A pharmacodynamics pre-surgical study of LEE011 in early breast cancer patients (MONALEESA-1). Available at: http://clinicaltrials.gov/show/NCT01919229. Accessed May 27, 2014.
48. NIH. National Cancer Institute. Study of LEE011 with fulvestrant and BYL719 or BKM120 in advanced breast cancer. Available at: http://www.cancer.gov/clinicaltrials/search/view?cdrid=759365&version=HealthProfessional&protocolsearchid=12773476. Accessed May 27, 2014.
49. Clinicaltrials.gov [Web site]. Study of efficacy and safety of LEE011 in postmenopausal women with advanced breast cancer. (MONALEESA-2). Available at: http://clinicaltrials.gov/show/NCT01958021. Accessed May 27, 2014.
50. Clinicaltrials.gov [Web site]. Study of efficacy and safety in premenopausal women with hormone receptor positive, HER2-negative advanced breast cancer (MONALEESA-7). Available at: https://clinicaltrials.gov/ct2/show/NCT02278120 Accessed August 12, 2015.
51. Clinicaltrials.gov [Web site]. A phase 2 neoadjuvant study of abemaciclib (LY2835219) in postmenopausal women with hormone receptor positive, HER2 negative breast cancer (neoMONARCH). Available at: https://clinicaltrials.gov/ct2/show/NCT02441946?term=abemaciclib&rank=3. Accessed May 15, 2015.
52. Clinicaltrials.gov [Web site]. A study of abemaciclib (LY2835219) in participants with breast cancer that has spread to the brain. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02308020?term=abemaciclib&rank=6. Accessed August 12, 2015.
53. NIH. National Cancer Institute. A study of LY2835219 combined with fulvestrant in women with hormone receptor positive HER2 negative breast cancer. Available at: http://www.cancer.gov/clinicaltrials/search/view?cdrid=759807&version=HealthProfessional&protocolsearchid=12773524. Accessed May 27, 2014.
54. Clinicaltrials.gov [Web site]. A study of nonsteroidal aromatase inhibitors plus abemaciclib (LY2835219) in postmenopausal women with breast cancer (MONARCH 3). Available at: https://clinicaltrials.gov/ct2/show/NCT02246621?term=abemaciclib&rank=7. Accessed May 15, 2015.
55. K.T. Flaherty, P.M. Lorusso, A. Demichele, and et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer Clin Cancer Res 18 2012 568 576
56. G.K. Schwartz, P.M. LoRusso, M.A. Dickson, and et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (schedule 2/1) Br J Cancer 104 2011 1862 1868
57. Finn RS, Crown JP, Lang I, et al. Final results of a randomized phase II study of PD 0332991, a cyclin-dependent kinase (CDK-4/6 inhibitor), in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1; TRIO-18). Presented at the American Association for Cancer Research, San Diego, CA, 2014 (abstract CT101).
58. Finn RS, Crown JP, Boer K, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first line treatment of ER+/HER2- advanced breast cancer (BC). Presented at the IMPAKT Breast Cancer Conference, Brussels, Belgium, 2012 (abstract 1000).
59. Finn RS, Crown JP, Lang I, et al. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first line treatment of ER+/HER2- advanced breast cancer (BC). Presented at the SABCS, San Antonio, TX (abstract S1-6), 2012.
60. A study of palbociclib (PD-0332991) + letrozole vs. letrozole for 1st line treatment of postmenopausal women with ER+/HER2- advanced breast cancer (PALOMA-2). National Cancer Institute at the National Institutes of Health Clinical Trials. Available at: https://clinicaltrials.gov/ct2/show/NCT01740427 Accessed August 12, 2015.
61. N.C. Turner, J. Ro, F. Andre, and et al. PALOMA3: a double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (abstract LBA502) J Clin Oncol suppl 2015 33
62. +) breast cancer: a phase II feasibility study (abstract TPS654). Presented at ASCO, Chicago, IL, May 2014.
63. PD0332991/paclitaxel in advanced breast cancer. National Cancer Institute at the National Institutes of Health Clinical Trials. Available at: https://clinicaltrials.gov/show/NCT01320592 Accessed August 12, 2015.
64. Clark AS, O'Dwyer PJ, Heitjan D, et al. A phase I trial of palbociclib and paclitaxel in metastatic breast cancer (abstract 527). Presented at ASCO, Chicago, IL, May 2014.
65. J.R. Infante, G.I. Shapiro, P.O. Witteveen, and et al. Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas (abstract A276) Mol Cancer Ther 2013 12
66. Bardia A, Modi S, Chavez-Mac Gregor M, et al. Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2- metastatic breast cancer (abstract 535). Presented at ASCO, Chicago, IL, May 2014.
67. D. Juric, E. Hamilton, L. Estévez, and et al. Phase Ib/II study of LEE011 and BYL719 and letrozole in ER+, HER2- breast cancer: safety, preliminary efficacy and molecular analysis (abstract P5-19-24) Cancer Res 75 9 suppl 2015
68. +) metastatic breast cancer (abstract 534). Presented at ASCO, Chicago, IL, May 2014.
69. Patnaik A, Rosen LS, Tolaney SM et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer (abstract CT 232). Presented at the American Association for Cancer Research, San Diego, CA, April 2014.
70. Clinicaltrials.gov [Web site]. A study of LY2835219 in combination with therapies for breast cancer that has spread. Available at: https://clinicaltrials.gov/ct2/show/record/NCT02057133. Accessed May 27, 2014.
71. A study of LY2835219 in participants with previously treated breast cancer that has spread. National Cancer Institute at the National Institutes of Health Clinical Trials. Available at: https://clinicaltrials.gov/ct2/show/NCT02102490 Accessed August 12, 2015.
72. Clinicaltrials.gov [Web site]. A phase 1 study of LY2835219 in participants with advanced cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT01394016 Accessed August 12, 2015.
73. NIH. National Cancer Institute. A study of LY2835219 in participants with cancer. Available at: https://clinicaltrials.gov/ct2/show/NCT02117648 Accessed August 12, 2015.
74. Clinicaltrials.gov [Web site]. A study of abemaciclib in participants with varying degrees of liver impairment. National Cancer Institute at the National Institutes of Health Clinical Trials. Available at: https://clinicaltrials.gov/ct2/show/NCT02387814?term=abemaciclib&rank=2. Accessed May 15, 2015.
75. Munster PN, Hamilton EP, Franklin C, et al. Phase Ib study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2- BC) (abstract 533). Presented at ASCO, Chicago, IL, May 2014.